AKT1 is altered in 1.4% of soft tissue sarcoma patients [2].

AKT1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ALK is altered in 1.36% of soft tissue sarcoma patients [2].

ALK is an inclusion eligibility criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain ALK status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

APH1A is altered in 1.49% of soft tissue sarcoma patients [2].

APH1A is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains APH1A status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ARAF is altered in 0.87% of soft tissue sarcoma patients [2].

ARAF is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ARID1A is altered in 3.1% of soft tissue sarcoma patients [2].

ARID1A is an inclusion eligibility criterion in 2 clinical trials for soft tissue sarcoma, of which 0 are open and 2 are closed. Of the trials that contain ARID1A status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (0 open) [3].

ATM is altered in 2.52% of soft tissue sarcoma patients [2].

ATM is an inclusion eligibility criterion in 4 clinical trials for soft tissue sarcoma, of which 3 are open and 1 is closed. Of the trials that contain ATM status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

ATR is altered in 1.26% of soft tissue sarcoma patients [2].

ATR is an inclusion eligibility criterion in 4 clinical trials for soft tissue sarcoma, of which 3 are open and 1 is closed. Of the trials that contain ATR status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

ATRX is altered in 8.35% of soft tissue sarcoma patients [2].

ATRX is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ATRX status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

AXL is altered in 1.15% of soft tissue sarcoma patients [2].

AXL is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains AXL status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BARD1 is altered in 0.89% of soft tissue sarcoma patients [2].

BARD1 is an inclusion eligibility criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain BARD1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

BCL2 is altered in 0.36% of soft tissue sarcoma patients [2].

BCL2 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains BCL2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BCL6 is altered in 0.56% of soft tissue sarcoma patients [2].

BCL6 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRAF is altered in 0.86% of soft tissue sarcoma patients [2].

BRAF is an inclusion eligibility criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

BRCA1 is altered in 0.95% of soft tissue sarcoma patients [2].

BRCA1 is an inclusion eligibility criterion in 4 clinical trials for soft tissue sarcoma, of which 3 are open and 1 is closed. Of the trials that contain BRCA1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

BRCA2 is altered in 2.65% of soft tissue sarcoma patients [2].

BRCA2 is an inclusion eligibility criterion in 4 clinical trials for soft tissue sarcoma, of which 3 are open and 1 is closed. Of the trials that contain BRCA2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

BRIP1 is altered in 0.71% of soft tissue sarcoma patients [2].

BRIP1 is an inclusion eligibility criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain BRIP1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

C11orf30 is altered in 0.31% of soft tissue sarcoma patients [2].

C11orf30 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains C11orf30 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

CCND1 is altered in 0.81% of soft tissue sarcoma patients [2].

CCND1 is an inclusion eligibility criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain CCND1 status and soft tissue sarcoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CCND2 is altered in 1.42% of soft tissue sarcoma patients [2].

CCND2 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCND3 is altered in 0.66% of soft tissue sarcoma patients [2].

CCND3 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND3 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCNE1 is altered in 1.38% of soft tissue sarcoma patients [2].

CCNE1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains CCNE1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

CDK12 is altered in 0.85% of soft tissue sarcoma patients [2].

CDK12 is an inclusion eligibility criterion in 4 clinical trials for soft tissue sarcoma, of which 3 are open and 1 is closed. Of the trials that contain CDK12 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

CDK4 is altered in 2.41% of soft tissue sarcoma patients [2].

CDK4 is an inclusion eligibility criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 status and soft tissue sarcoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CDK6 is altered in 0.51% of soft tissue sarcoma patients [2].

CDK6 is an inclusion eligibility criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 status and soft tissue sarcoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CDKN2A is altered in 13.44% of soft tissue sarcoma patients [2].

CDKN2A is an inclusion eligibility criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain CDKN2A status and soft tissue sarcoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CHEK1 is altered in 0.47% of soft tissue sarcoma patients [2].

CHEK1 is an inclusion eligibility criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain CHEK1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

CHEK2 is altered in 1.22% of soft tissue sarcoma patients [2].

CHEK2 is an inclusion eligibility criterion in 4 clinical trials for soft tissue sarcoma, of which 3 are open and 1 is closed. Of the trials that contain CHEK2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

CRKL is altered in 1.3% of soft tissue sarcoma patients [2].

CRKL is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CSF1R is altered in 0.51% of soft tissue sarcoma patients [2].

CSF1R is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

DDIT3 is altered in 0.08% of soft tissue sarcoma patients [2].

DDIT3 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains DDIT3 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

DLL4 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains DLL4 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

EGFR is altered in 1.3% of soft tissue sarcoma patients [2].

EGFR is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EPCAM is altered in 0.43% of soft tissue sarcoma patients [2].

EPCAM is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 is altered in 0.91% of soft tissue sarcoma patients [2].

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB3 is altered in 1.85% of soft tissue sarcoma patients [2].

ERBB3 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERCC2 is altered in 0.85% of soft tissue sarcoma patients [2].

ERCC2 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ERCC2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ERCC3 is altered in 0.72% of soft tissue sarcoma patients [2].

ERCC3 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ERCC3 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ERCC4 is altered in 0.5% of soft tissue sarcoma patients [2].

ERCC4 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ERCC4 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ERCC5 is altered in 1.16% of soft tissue sarcoma patients [2].

ERCC5 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ERCC5 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

ERCC6 is altered in 0.49% of soft tissue sarcoma patients [2].

ERCC6 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ERCC6 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

EWSR1 is altered in 5.57% of soft tissue sarcoma patients [2].

EWSR1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains EWSR1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

EXO1 is altered in 1.93% of soft tissue sarcoma patients [2].

EXO1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains EXO1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCA is altered in 1.17% of soft tissue sarcoma patients [2].

FANCA is an inclusion eligibility criterion in 4 clinical trials for soft tissue sarcoma, of which 3 are open and 1 is closed. Of the trials that contain FANCA status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

FANCB is altered in 0.97% of soft tissue sarcoma patients [2].

FANCB is an inclusion eligibility criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain FANCB status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

FANCC is altered in 0.72% of soft tissue sarcoma patients [2].

FANCC is an inclusion eligibility criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain FANCC status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

FANCD2 is altered in 3.59% of soft tissue sarcoma patients [2].

FANCD2 is an inclusion eligibility criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain FANCD2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

FANCE is altered in 0.31% of soft tissue sarcoma patients [2].

FANCE is an inclusion eligibility criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain FANCE status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

FANCF is altered in 0.78% of soft tissue sarcoma patients [2].

FANCF is an inclusion eligibility criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain FANCF status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

FANCG is altered in 0.63% of soft tissue sarcoma patients [2].

FANCG is an inclusion eligibility criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain FANCG status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

FANCI is altered in 1.79% of soft tissue sarcoma patients [2].

FANCI is an inclusion eligibility criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain FANCI status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

FANCL is altered in 0.85% of soft tissue sarcoma patients [2].

FANCL is an inclusion eligibility criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain FANCL status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

FANCM is altered in 2.43% of soft tissue sarcoma patients [2].

FANCM is an inclusion eligibility criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain FANCM status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

FBXW7 is altered in 1.2% of soft tissue sarcoma patients [2].

FBXW7 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains FBXW7 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

FGFR1 is altered in 1.75% of soft tissue sarcoma patients [2].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR2 is altered in 0.88% of soft tissue sarcoma patients [2].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR3 is altered in 1.18% of soft tissue sarcoma patients [2].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT1 is altered in 1.1% of soft tissue sarcoma patients [2].

FLT1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 is altered in 1.1% of soft tissue sarcoma patients [2].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT4 is altered in 1.75% of soft tissue sarcoma patients [2].

FLT4 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FOXO1 is altered in 1.55% of soft tissue sarcoma patients [2].

FOXO1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FOXO1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

HDAC1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains HDAC1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

HDAC2 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains HDAC2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

HRAS is altered in 1.29% of soft tissue sarcoma patients [2].

HRAS is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

JAG1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains JAG1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KDM6A is altered in 1.11% of soft tissue sarcoma patients [2].

KDM6A is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KDR is altered in 2.64% of soft tissue sarcoma patients [2].

KDR is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT is altered in 30.77% of soft tissue sarcoma patients [2].

KIT is an inclusion eligibility criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain KIT status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

KMT2C is altered in 2.12% of soft tissue sarcoma patients [2].

KMT2C is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2C status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KMT2D is altered in 5.11% of soft tissue sarcoma patients [2].

KMT2D is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KRAS is altered in 1.55% of soft tissue sarcoma patients [2].

KRAS is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAML1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MAML1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MAP2K1 is altered in 0.2% of soft tissue sarcoma patients [2].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K2 is altered in 0.52% of soft tissue sarcoma patients [2].

MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K4 is altered in 1.69% of soft tissue sarcoma patients [2].

MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP3K1 is altered in 1.25% of soft tissue sarcoma patients [2].

MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAPK1 is altered in 1.09% of soft tissue sarcoma patients [2].

MAPK1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain MCPH1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

MDM2 is altered in 3.59% of soft tissue sarcoma patients [2].

MDM2 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MDM2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MDM4 is altered in 1.03% of soft tissue sarcoma patients [2].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MDM4 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MET is altered in 1.48% of soft tissue sarcoma patients [2].

MET is an inclusion eligibility criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain MET status and soft tissue sarcoma as inclusion criteria, 2 are phase 2 (2 open) [3].

MLF1 is altered in 0.46% of soft tissue sarcoma patients [2].

MLF1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MLF1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MLH1 is altered in 0.67% of soft tissue sarcoma patients [2].

MLH1 is an inclusion eligibility criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain MLH1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 2 are phase 2 (2 open) [3].

MLH3 is altered in 2.46% of soft tissue sarcoma patients [2].

MLH3 is an inclusion eligibility criterion in 2 clinical trials for soft tissue sarcoma, of which 1 is open and 1 is closed. Of the trials that contain MLH3 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].

MRE11A is altered in 0.76% of soft tissue sarcoma patients [2].

MRE11A is an inclusion eligibility criterion in 4 clinical trials for soft tissue sarcoma, of which 3 are open and 1 is closed. Of the trials that contain MRE11A status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

MSH2 is altered in 1.25% of soft tissue sarcoma patients [2].

MSH2 is an inclusion eligibility criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain MSH2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 2 are phase 2 (2 open) [3].

MSH3 is altered in 1.06% of soft tissue sarcoma patients [2].

MSH3 is an inclusion eligibility criterion in 2 clinical trials for soft tissue sarcoma, of which 1 is open and 1 is closed. Of the trials that contain MSH3 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].

MSH6 is altered in 1.35% of soft tissue sarcoma patients [2].

MSH6 is an inclusion eligibility criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain MSH6 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 2 are phase 2 (2 open) [3].

MST1R is altered in 1.19% of soft tissue sarcoma patients [2].

MST1R is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MST1R status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MTOR is altered in 1.74% of soft tissue sarcoma patients [2].

MTOR is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MUTYH is altered in 0.52% of soft tissue sarcoma patients [2].

MUTYH is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MUTYH status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MYC is altered in 2.52% of soft tissue sarcoma patients [2].

MYC is an inclusion eligibility criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain MYC status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

MYCN is altered in 1.01% of soft tissue sarcoma patients [2].

MYCN is an inclusion eligibility criterion in 3 clinical trials for soft tissue sarcoma, of which 3 are open and 0 are closed. Of the trials that contain MYCN status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is no phase specified (1 open) [3].

NBN is altered in 0.74% of soft tissue sarcoma patients [2].

NBN is an inclusion eligibility criterion in 4 clinical trials for soft tissue sarcoma, of which 3 are open and 1 is closed. Of the trials that contain NBN status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

NCSTN is altered in 1.43% of soft tissue sarcoma patients [2].

NCSTN is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains NCSTN status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NF1 is altered in 5.66% of soft tissue sarcoma patients [2].

NF1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NOTCH1 is altered in 2.31% of soft tissue sarcoma patients [2].

NOTCH1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NOTCH2 is altered in 2.1% of soft tissue sarcoma patients [2].

NOTCH2 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NOTCH3 is altered in 1.76% of soft tissue sarcoma patients [2].

NOTCH3 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH3 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NOTCH4 is altered in 1.09% of soft tissue sarcoma patients [2].

NOTCH4 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH4 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NPM1 is altered in 0.44% of soft tissue sarcoma patients [2].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains NPM1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

NR4A3 is altered in 0.35% of soft tissue sarcoma patients [2].

NR4A3 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains NR4A3 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

NRAS is altered in 1.79% of soft tissue sarcoma patients [2].

NRAS is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NRG1 is altered in 0.22% of soft tissue sarcoma patients [2].

NRG1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains NRG1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK1 is altered in 2.17% of soft tissue sarcoma patients [2].

NTRK1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK2 is altered in 0.66% of soft tissue sarcoma patients [2].

NTRK2 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK3 is altered in 2.01% of soft tissue sarcoma patients [2].

NTRK3 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PALB2 is altered in 0.85% of soft tissue sarcoma patients [2].

PALB2 is an inclusion eligibility criterion in 4 clinical trials for soft tissue sarcoma, of which 3 are open and 1 is closed. Of the trials that contain PALB2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

PARP1 is altered in 0.74% of soft tissue sarcoma patients [2].

PARP1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains PARP1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

PARP2 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains PARP2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

PCNA is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PCNA status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFB is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFB status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PDGFRA is altered in 5.86% of soft tissue sarcoma patients [2].

PDGFRA is an inclusion eligibility criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

PDGFRB is altered in 1.43% of soft tissue sarcoma patients [2].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PIK3CA is altered in 2.49% of soft tissue sarcoma patients [2].

PIK3CA is an inclusion eligibility criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3CA status and soft tissue sarcoma as inclusion criteria, 2 are phase 2 (2 open) [3].

PMS1 is altered in 0.69% of soft tissue sarcoma patients [2].

PMS1 is an inclusion eligibility criterion in 2 clinical trials for soft tissue sarcoma, of which 1 is open and 1 is closed. Of the trials that contain PMS1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].

PMS2 is altered in 1.3% of soft tissue sarcoma patients [2].

PMS2 is an inclusion eligibility criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain PMS2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 2 are phase 2 (2 open) [3].

POLD1 is altered in 0.89% of soft tissue sarcoma patients [2].

POLD1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains POLD1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

POLE is altered in 1.46% of soft tissue sarcoma patients [2].

POLE is an inclusion eligibility criterion in 2 clinical trials for soft tissue sarcoma, of which 1 is open and 1 is closed. Of the trials that contain POLE status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [3].

PPP2R1A is altered in 0.97% of soft tissue sarcoma patients [2].

PPP2R1A is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains PPP2R1A status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

PPP2R2A is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains PPP2R2A status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

PTEN is altered in 4.51% of soft tissue sarcoma patients [2].

PTEN is an inclusion eligibility criterion in 3 clinical trials for soft tissue sarcoma, of which 3 are open and 0 are closed. Of the trials that contain PTEN status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

RAD50 is altered in 0.76% of soft tissue sarcoma patients [2].

RAD50 is an inclusion eligibility criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain RAD50 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

RAD51 is altered in 0.56% of soft tissue sarcoma patients [2].

RAD51 is an inclusion eligibility criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain RAD51 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

RAD51B is altered in 1.19% of soft tissue sarcoma patients [2].

RAD51B is an inclusion eligibility criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain RAD51B status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

RAD51C is altered in 0.49% of soft tissue sarcoma patients [2].

RAD51C is an inclusion eligibility criterion in 4 clinical trials for soft tissue sarcoma, of which 3 are open and 1 is closed. Of the trials that contain RAD51C status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

RAD51D is altered in 0.18% of soft tissue sarcoma patients [2].

RAD51D is an inclusion eligibility criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain RAD51D status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

RAD54L is altered in 0.22% of soft tissue sarcoma patients [2].

RAD54L is an inclusion eligibility criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain RAD54L status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

RAF1 is altered in 0.8% of soft tissue sarcoma patients [2].

RAF1 is an inclusion eligibility criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain RAF1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RB1 is altered in 9.94% of soft tissue sarcoma patients [2].

RB1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

RET is altered in 1.61% of soft tissue sarcoma patients [2].

RET is an inclusion eligibility criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain RET status and soft tissue sarcoma as inclusion criteria, 2 are phase 2 (2 open) [3].

RFC1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RFC1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC2 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RFC2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC3 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RFC3 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC4 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RFC4 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC5 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RFC5 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ROS1 is altered in 2.76% of soft tissue sarcoma patients [2].

ROS1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RPA1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA2 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA3 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RPA3 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA4 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RPA4 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SLX4 is altered in 1.43% of soft tissue sarcoma patients [2].

SLX4 is an inclusion eligibility criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain SLX4 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

SMARCA2 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SMARCA4 is altered in 1.71% of soft tissue sarcoma patients [2].

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SMARCB1 is altered in 1.65% of soft tissue sarcoma patients [2].

SMARCB1 is an inclusion eligibility criterion in 2 clinical trials for soft tissue sarcoma, of which 0 are open and 2 are closed. Of the trials that contain SMARCB1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (0 open) [3].

SRC is altered in 0.46% of soft tissue sarcoma patients [2].

SRC is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains SRC status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SS18 is altered in 2.35% of soft tissue sarcoma patients [2].

SS18 is an inclusion eligibility criterion in 2 clinical trials for soft tissue sarcoma, of which 1 is open and 1 is closed. Of the trials that contain SS18 status and soft tissue sarcoma as inclusion criteria, 2 are phase 1 (1 open) [3].

SSBP1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains SSBP1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SSX1 is altered in 1.05% of soft tissue sarcoma patients [2].

SSX1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains SSX1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SSX2 is altered in 1.18% of soft tissue sarcoma patients [2].

SSX2 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains SSX2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SSX2B is altered in 0.26% of soft tissue sarcoma patients [2].

SSX2B is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains SSX2B status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SSX4 is altered in 0.74% of soft tissue sarcoma patients [2].

SSX4 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains SSX4 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

STAG2 is altered in 1.08% of soft tissue sarcoma patients [2].

STAG2 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains STAG2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

STK11 is altered in 1.01% of soft tissue sarcoma patients [2].

STK11 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains STK11 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

TFE3 is altered in 0.95% of soft tissue sarcoma patients [2].

TFE3 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains TFE3 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TP53 is altered in 18.91% of soft tissue sarcoma patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

TSC1 is altered in 1.64% of soft tissue sarcoma patients [2].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TSC2 is altered in 2.46% of soft tissue sarcoma patients [2].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VHL is altered in 0.27% of soft tissue sarcoma patients [2].

VHL is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

WT1 is altered in 3.71% of soft tissue sarcoma patients [2].

WT1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

XRCC1 is altered in 0.97% of soft tissue sarcoma patients [2].

XRCC1 is an inclusion eligibility criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains XRCC1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].